Drug information of Levobetaxolol


Drug group:

Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It has been discontinued.

Mechanism of effect

Levobetaxolol is a cardioselective beta-1–adrenergic antagonist. It appears to lower elevated intraocular pressure by reducing aqueous humor production.


Topically applied levobetaxolol exerts a minor effect on heart rate and blood pressure.

Levobetaxolol does not have significant membrane-stabilizing (local anesthetic) activity.


Absorption: Systemic absorption has occurred to some degree with other beta adrenergic blocking agents.

Half-life: Approximately 20 hours

Onset of action: Approximately 30 minutes, after topical administration

Time to peak plasma concentration: Approximately 3 hours, after topical administration

Peak plasma concentration: Mean of 0.5 nanograms/milliliter

Time to peak effect: Approximately 2 hours after topical administration

Duration of action: Approximately 12 hours, after a single topical dose

Drug indications

increased ocular tension


Usual Adult Dose
Open-angle glaucoma or Ocular hypertension
Topical, to the conjunctiva, 1 drop into the affected eye, two times a day
Usual Pediatric Dose
Safety and efficacy have not been established for the use of levobetaxolol in children


» Anaphylactic reactions, severe, history of or
» Atopy, history of (risk of developing unresponsiveness to usual doses of epinephrine used to treat anaphylactic reactions)

» Cardiac failure, history of or
Heart block, history of   (in clinical studies, levobetaxolol has been shown to have a minor effect on heart rate and blood pressure; treatment should be discontinued at the first signs of cardiac failure)

» Diabetes mellitus or
» Hypoglycemia  (ophthalmic beta-adrenergic receptor blocking agents may mask or suppress some of the signs and symptoms of acute hypoglycemia in patients with diabetes)

Glaucoma, angle-closure (when used to reduce elevated intraocular pressure, levobetaxolol must be used with a miotic agent because if it is used alone, it is expected to have little or no effect on the pupil)

Myasthenic conditions    (potentiation of muscle weakness associated with myasthenic conditions has been reported after beta-adrenergic receptor blockade)

» Pulmonary function impairment (acute asthmatic attacks and pulmonary distress have been reported during treatment with ophthalmic beta-adrenergic receptor blocking agents)

Surgery, major    (gradual withdrawal of beta-adrenergic receptor blocking agents may be indicated prior to induction of general anesthesia due to the potential for impairment of the cardiac response to beta-adrenergically mediated sympathetic reflex stimuli)

» Thyrotoxicosis (certain signs and symptoms of hyperthyroidism, such as tachycardia, may be masked by beta-adrenergic blocking agents; abrupt withdrawal may precipitate a thyroid storm)

Points of recommendation

» Removing contact lenses before using medication

Shaking medication well before using

Washing hands before using medication; Washing hands again immediately after using medication

Preventing contamination: Not touching dropper to any surface; keeping container tightly closed

Applying the missed dose as soon as possible; if almost time for next dose, skipping missed dose and going back to regular dosing schedule; not doubling doses

» Regular visits to physician to check progress

» Caution when driving a car or using machinery because of possible blurred vision or dizziness

» Diabetic patients: May mask some signs of hypoglycemia

Pregnancy level

Group c - Not adequate studies in pregnant women

Related drugs

Betaxolol , Timolol , Levobunolol , Carteolol

Ask a Pharmacist

User's questions
    No comments yet.